Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

Current Opinion in Virology

Volumn 8, Issue , 2014, Pages 10-15

  Beaucourt, Stéphanie ^a   Vignuzzi, Marco ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; RIBAVIRIN; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARENAVIRUS; ARTICLE; BORNA DISEASE VIRUS; BUNYAVIRUS; CELL TYPE; CHIKUNGUNYA ALPHAVIRUS; CORONAVIRUS; FLAVIVIRUS; IN VITRO STUDY; NONHUMAN; ORTHOMYXOVIRUS; PAPILLOMA VIRUS; PICORNAVIRUS; PRIORITY JOURNAL; VIRUS REPLICATION; DRUG DEVELOPMENT; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; PROCEDURES; VIRUS;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HUMANS; RIBAVIRIN; VIRUS REPLICATION; VIRUSES;

EID: 84901253888     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.04.011     Document Type: Review

References (51)

1. A.C. Cooper, N.C. Banasiak, and P.J. Allen Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions Pediatr Nurs 29 2003 452 456
2. J.B. McCormick, I.J. King, P.A. Webb, C.L. Scribner, R.B. Craven, K.M. Johnson, L.H. Elliott, and R. Belmont-Williams Lassa fever. Effective therapy with ribavirin N Engl J Med 314 1986 20 26 (Pubitemid 16183064)
3. S.P. Fisher-Hoch, J.A. Khan, S. Rehman, S. Mirza, M. Khurshid, and J.B. McCormick Crimean Congo-haemorrhagic fever treated with oral ribavirin Lancet 346 1995 472 475
4. M.S. Bronze, and R.A. Greenfield Therapeutic options for diseases due to potential viral agents of bioterrorism Curr Opin Investig Drugs 4 2003 172 178 (Pubitemid 36383013)
5. J.-M. Pawlotsky, H. Dahari, A.U. Neumann, C. Hezode, G. Germanidis, I. Lonjon, L. Castera, and D. Dhumeaux Antiviral action of ribavirin in chronic hepatitis C Gastroenterology 126 2004 703 714 (Pubitemid 38298318)
6. J.D. Graci, and C.E. Cameron Mechanisms of action of ribavirin against distinct viruses Rev Med Virol 16 2005 37 48 (Pubitemid 43133592)
7. N.T. Binh, C. Wakai, A. Kawaguchi, and K. Nagata Involvement of the N-terminal portion of influenza virus RNA polymerase subunit PB1 in nucleotide recognition Biochem Biophys Res Commun 443 2014 975 979
8. Y. Debing, S.U. Emerson, Y. Wang, Q. Pan, J. Balzarini, K. Dallmeier, and J. Neyts Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon Antimicrob Agents Chemother 58 2014 267 273
9. K. Mori, M. Ikeda, Y. Ariumi, H. Dansako, T. Wakita, and N. Kato Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system Virus Res 157 2011 61 70
10. A.M. Ortega-Prieto, J. Sheldon, A. Grande-Pérez, H. Tejero, J. Gregori, J. Quer, J.I. Esteban, E. Domingo, and C. Perales Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis PLoS ONE 8 2013 e71039
11. C. Perales, N.M. Beach, I. Gallego, M.E. Soria, J. Quer, J.I. Esteban, C. Rice, E. Domingo, and J. Sheldon Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype J Virol 87 2013 7593 7607
12. H. Moreno, I. Gallego, N. Sevilla, J.C. la Torre de, E. Domingo, and V. Martín Ribavirin can be mutagenic for arenaviruses J Virol 85 2011 7246 7255
13. Y. Sun, D.-H. Chung, Y.-K. Chu, C.B. Jonsson, and W.B. Parker Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase Antimicrob Agents Chemother 51 2007 84 88 (Pubitemid 46047691)
14. D.-H. Chung, Y. Sun, W.B. Parker, J.B. Arterburn, A. Bartolucci, and C.B. Jonsson Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus J Virol 81 2007 11722 11729 (Pubitemid 47623804)
15. N.R. Shah, A. Sunderland, and V.Z. Grdzelishvili Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin PLoS ONE 5 2010 e11265
16. D. Falzarano, E. de Wit, C. Martellaro, J. Callison, V.J. Munster, and H. Feldmann Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Sci Rep 3 2013 1686
17. K.D. Ibarra, M.K. Jain, and J.K. Pfeiffer Host-based ribavirin resistance influences hepatitis C virus replication and treatment response J Virol 85 2011 7273 7283
18. C. Perales, R. Agudo, H. Tejero, S.C. Manrubia, and E. Domingo Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections PLoS Pathog 5 2009 e1000658
19. H. Moreno, H. Tejero, J.C. la Torre de, E. Domingo, and V. Martín Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection PLoS ONE 7 2012 e32550
20. J.M. Werner, E. Serti, X. Chepa-Lotrea, J. Stoltzfus, G. Ahlenstiel, M. Noureddin, J.J. Feld, T.J. Liang, Y. Rotman, and B. Rehermann Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection Hepatology 2014 10.1002/hep.27092
21. V. Soriano, M. Puoti, M. Sulkowski, A. Cargnel, Y. Benhamou, M. Peters, S. Mauss, N. Bräu, A. Hatzakis, and S. Pol et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel AIDS 21 2007 1073 1089 (Pubitemid 46763278)
22. N.K. Shrestha, and D.J. Hamrock Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin Clin Infect Dis 51 2010 e4 e6
23. M.H.P. Pavan, P.E.N.F. Velho, A.G. Vigani, F.L. Gonçalves, and F.H. Aoki Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin Braz J Infect Dis 11 2007 383 384 (Pubitemid 47616506)
24. C. Mosa, A. Trizzino, A. Trizzino, F. Di Marco, P. D'Angelo, and P. Farruggia Treatment of human papillomavirus infection with interferon alpha and ribavirin in a patient with acquired aplastic anemia Int J Infect Dis 2014 10.1016/j.ijid.2013.11.021
25. J. Dietz, S.-E. Schelhorn, D. Fitting, U. Mihm, S. Susser, M.-W. Welker, C. Füller, M. Däumer, G. Teuber, and H. Wedemeyer et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients J Virol 87 2013 6172 6181
26. J.M. Cuevas, F. González-Candelas, A. Moya, and R. Sanjuán Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo J Virol 83 2009 5760 5764
27. N. Kamar, J. Izopet, S. Tripon, M. Bismuth, S. Hillaire, J. Dumortier, S. Radenne, A. Coilly, V. Garrigue, and L. D'Alteroche et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients N Engl J Med 370 2014 1111 1120
28. J.R. Marcelin, J.W. Wilson, R.R. Razonable, and Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients Transpl Infect Dis 16 2014 242 250
29. S.B. Ozbey, C. Kader, A. Erbay, and O. Ergönül Early use of ribavirin is beneficial in crimean-congo hemorrhagic fever Vector Borne Zoonotic Dis 14 2014 300 302
30. O. Ruuskanen, M. Waris, and L. Kainulainen Treatment of persistent rhinovirus infection with pegylated interferon-α2a and ribavirin in patients with hypogammaglobulinemia Clin Infect Dis 2014 10.1093/cid/ciu169
31. D. Falzarano, E. de Wit, A.L. Rasmussen, F. Feldmann, A. Okumura, D.P. Scott, D. Brining, T. Bushmaker, C. Martellaro, and L. Baseler et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Nat Med 19 2013 1313 1317
32. M. Ogg, C.B. Jonsson, J.V. Camp, and J.W. Hooper Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome - after intranasal exposure to Andes virus Viruses 5 2013 2704 2720
33. J.K. Pfeiffer, and K. Kirkegaard A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity Proc Natl Acad Sci U S A 100 2003 7289 7294 (Pubitemid 36706431)
34. M. Vignuzzi, E. Wendt, and R. Andino Engineering attenuated virus vaccines by controlling replication fidelity Nat Med 14 2008 154 161 (Pubitemid 351214560)
35. S. Sadeghipour, E.J. Bek, and P.C. McMinn Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture J Virol 87 2013 1759 1769
36. J. Zeng, H. Wang, X. Xie, D. Yang, G. Zhou, and L. Yu An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo Antiviral Res 100 2013 1 7
37. L.I. Levi, N.F. Gnädig, S. Beaucourt, M.J. McPherson, B. Baron, J.J. Arnold, and M. Vignuzzi Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds PLoS Pathog 6 2010 e1001163
38. T. Meng, and J. Kwang Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice J Virol 88 2014 5803 5815
39. L.L. Coffey, Y. Beeharry, A.V. Bordería, H. Blanc, and M. Vignuzzi Arbovirus high fidelity variant loses fitness in mosquitoes and mice Proc Natl Acad Sci U S A 108 2011 16038 16043
40. J.K. Pfeiffer, and K. Kirkegaard Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA J Virol 79 2005 2346 2355 (Pubitemid 40204589)
41. D.A. Feigelstock, K.B. Mihalik, and S.M. Feinstone Selection of hepatitis C virus resistant to ribavirin Virol J 8 2011 402
42. K.B. Mihalik, and D.A. Feigelstock Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs PLoS ONE 8 2013 e74027
43. J. Zeng, H. Wang, X. Xie, C. Li, G. Zhou, D. Yang, and L. Yu Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence J Virol 2014 10.1128/JVI.03594-13
44. A. Arias, J.J. Arnold, M. Sierra, E.D. Smidansky, E. Domingo, and C.E. Cameron Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin J Virol 82 2008 12346 12355
45. C. Ferrer-Orta, M. Sierra, R. Agudo, I. la Higuera de, A. Arias, R. Perez-Luque, C. Escarmis, E. Domingo, and N. Verdaguer Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin J Virol 84 2010 6188 6199
46. N.F. Gnädig, S. Beaucourt, G. Campagnola, A.V. Bordería, M. Sanz-Ramos, P. Gong, H. Blanc, O.B. Peersen, and M. Vignuzzi Coxsackievirus B3 mutator strains are attenuated in vivo Proc Natl Acad Sci U S A 2012 10.1073/pnas.1204022109
47. K. Rozen-Gagnon, K.A. Stapleford, V. Mongelli, H. Blanc, A.-B. Failloux, M.-C. Saleh, and M. Vignuzzi Alphavirus mutator variants present host-specific defects and attenuation in mammalian and insect models PLoS Pathog 10 2014 e1003877
48. L.D. Eckerle, M.M. Becker, R.A. Halpin, K. Li, E. Venter, X. Lu, S. Scherbakova, R.L. Graham, R.S. Baric, and T.B. Stockwell et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing PLoS Pathogens 6 2010 e1000896
49. E.C. Smith, H. Blanc, M. Vignuzzi, and M.R. Denison Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics PLoS Pathog 9 2013 e1003565
50. M. Vignuzzi, J.K. Stone, and R. Andino Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications Virus Res 107 2005 173 181 (Pubitemid 40093090)
51. L.D. Eckerle, X. Lu, S.M. Sperry, L. Choi, and M.R. Denison High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants J Virol 81 2007 12135 12144 (Pubitemid 350085829)